following a full submission assessed under the orphan equivalent medicine process:
osimertinib (Tagrisso®) is accepted for use within NHSScotland.
Indication under review: in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
In an open-label, phase III study, addition of pemetrexed and platinum-based chemotherapy to osimertinib significantly improved progression-free survival in adults with NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- osimertinib (Tagrisso)
- SMC ID:
- SMC2736
- Indication:
In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 July 2025